Eli Lilly and Company (BCBA:LLYD)
Argentina · Delayed Price · Currency is ARS · Price in USD | Market Cap | 1,940.44T +73.5% |
| Revenue (ttm) | 131.85T +45.5% |
| Net Income | 42.06T +49.8% |
| EPS | 850.19 +50.7% |
| Shares Out | n/a |
| PE Ratio | 48.51 |
| Forward PE | 30.13 |
| Dividend | 131.94 (0.32%) |
| Ex-Dividend Date | Nov 13, 2026 |
| Volume | 4,407 |
| Open | 26.50 |
| Previous Close | 26.67 |
| Day's Range | 26.30 - 26.71 |
| 52-Week Range | 14.44 - 27.20 |
| Beta | n/a |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | Oct 29, 2026 |
About Eli Lilly and Company
Eli Lilly and Company discovers, develops, manufactures, and markets human pharmaceutical products in the United States, Europe, China, Japan, and internationally. The company offers cardiometabolic health products, including Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity. It also provi... [Read more]
Financial Performance
In 2025, Eli Lilly and Company's revenue was $65.18 billion, an increase of 44.70% compared to the previous year's $45.04 billion. Earnings were $20.64 billion, an increase of 94.90%.
Financial numbers in USD Financial StatementsNews
Eli Lilly price target raised to $1,600 from $1,440 at Cantor Fitzgerald
Cantor Fitzgerald analyst Carter Gould raised the firm’s price target on Eli Lilly (LLY) to $1,600 from $1,440 and keeps an Overweight rating on the shares. Commercial trends over Q4…
Eli Lilly price target raised to $1,600 from $1,400 at Freedom Broker
Freedom Broker analyst Ilya Zubkov raised the firm’s price target on Eli Lilly (LLY) to $1,600 from $1,400 and keeps a Buy rating on the shares. The company’s Q3 report…
Eli Lilly price target raised to $1,605 from $1,300 at Scotiabank
Scotiabank raised the firm’s price target on Eli Lilly (LLY) to $1,605 from $1,300 and keeps an Outperform rating on the shares. The firm believes Eli Lilly will maintain its…
Eli Lilly price target raised to $1,596 from $1,430 at Morgan Stanley
Morgan Stanley raised the firm’s price target on Eli Lilly (LLY) to $1,596 from $1,430 and keeps an Overweight rating on the shares.
Eli Lilly price target raised to $1,600 from $1,500 at RBC Capital
RBC Capital raised the firm’s price target on Eli Lilly (LLY) to $1,600 from $1,500 and keeps an Outperform rating on the shares. The company delivered another impressive quarter on…
Eli Lilly price target raised to $1,500 from $1,330 at Wells Fargo
Wells Fargo analyst Mohit Bansal raised the firm’s price target on Eli Lilly (LLY) to $1,500 from $1,330 and keeps an Overweight rating on the shares. The firm says Q4…
Eli Lilly price target raised to $1,612 from $1,376 at Truist
Truist raised the firm’s price target on Eli Lilly (LLY) to $1,612 from $1,376 and keeps a Buy rating on the shares. The company reported strong Q3 earnings growth, and…
Eli Lilly price target raised to $1,650 from $1,600 at Citi
Citi raised the firm’s price target on Eli Lilly (LLY) to $1,650 from $1,600 and keeps a Buy rating on the shares post the Q3 report. The firm says Lilly…
Eli Lilly price target raised to $1,573 from $1,413 at Goldman Sachs
Goldman Sachs raised the firm’s price target on Eli Lilly (LLY) to $1,573 from $1,413 and keeps a Buy rating on the shares. Eli Lilly rallied 6.6% after its third…
Eli Lilly price target raised to $1,550 from $1,300 at Argus
Argus analyst Jasper Hellweg raised the firm’s price target on Eli Lilly (LLY) to $1,550 from $1,300 and keeps a Buy rating on the shares after its Q3 earnings beat.
Eli Lilly price target raised to $1,650 from $1,500 at JPMorgan
JPMorgan analyst Chris Schott raised the firm’s price target on Eli Lilly (LLY) to $1,650 from $1,500 and keeps an Overweight rating on the shares post the Q3 report. The…
Eli Lilly price target raised to $1,625 from $1,425 at UBS
UBS raised the firm’s price target on Eli Lilly (LLY) to $1,625 from $1,425 and keeps a Buy rating on the shares. Eli Lilly significantly beat Q3 expectations and raised…
Eli Lilly price target raised to $1,610 from $1,440 at Jefferies
Jefferies raised the firm’s price target on Eli Lilly (LLY) to $1,610 from $1,440 and keeps a Buy rating on the shares. The firm notes the company posted a strong…
Big, fat demand for weight-loss drugs fuels Eli Lilly stock surge — as market cap hits $1.2 trillion
Eli Lilly stock hit a record high Thursday thanks to a stronger-than-expected earnings report fueled by sales of weight loss drugs Monjuaro and Zepbound.
Thursday's First Moves: FTNT Falls After Earnings, CAT Tumbles, LLY Rises
Fortinet (FTNT) shares sunk after earnings as the cybersecurity company's product revenue slowed. Caterpillar (CAT) showed a similar slowing story in its earnings despite posting a beat.
Eli Lilly CEO Dave Ricks on the obesity market: The room for expansion is dramatic
Eli Lilly, Dave Ricks joins 'Squawk on the Street' to discuss the company blowing past estimates, hike in sales outlook, and growing demand for weight-loss medication.
Eli Lilly and Company Earnings Call Transcript: Q3 2026
Q3 revenue grew 39% YoY and 2026 guidance rose, led by incretin demand and broader portfolio growth. Pipeline advances and major U.S. manufacturing investments support expansion, while price pressure and nonrecurring items shape the outlook.
Eli Lilly and Company Earnings release: Q3 2026
Eli Lilly and Company released its Q3 2026 earnings on October 29, 2026, summarizing the period's financial results.
Eli Lilly and Company Slides: Q3 2026
Eli Lilly and Company has posted slides in relation to its Q3 2026 quarterly earnings report, which was published on October 29, 2026.
Eli Lilly and Company Quarterly report: Q3 2026
Eli Lilly and Company has published its Q3 2026 quarterly earnings report on October 29, 2026.
Morning Movers: Caterpillar lower, Eli Lilly higher after earnings
Stock futures are lower as investors digest yesterday’s Federal Reserve hold and contrasting results from Alphabet and Microsoft. The Fed kept its benchmark interest-rate range unchanged at 3.75%-4%, ...
Eli Lilly's blowout quarter has a $5.5 billion twist
Eli Lilly LLY reported better-than-expected earnings for its fiscal Q3 on Thursday, offering fresh evidence that helps justify its trillion-dollar market cap. Sales reached $24.4 billion, while adjust...
Eli Lilly Revenue Climbs on Demand for Mounjaro, Zepbound
The pharmaceutical company's third-quarter profit came in at $6.45 billion, or $7.22 a share, compared with $5.58 billion, or $6.21 a share, a year earlier.
Eli Lilly Stock Jumps as Monster Earnings Powered by Mounjaro and Zepbound
Eli Lilly posts earnings that handily top estimates, fueled by strong performance in its metabolic portfolio.
Lilly raises outlook for third time this year as Zepbound sales soar.
The drug continues do dominate the market for prescription weight-loss drugs in the U.S.